Santhera closed the Chiesi agreement for the global rights (ex. North America) of Raxone in LHON ahead of time securing sufficient funds to reach the key turning point in 2020 with the anticipated EU conditional approval of Puldysa in DMD (80% success rate) and the vamorolone pivotal “VISION-DMD” trial results in DMD (35% success rate).

Key catalysts include:

  1. POL6014 phase I MAD trial results (H1 2020)
  2. Puldysa EU conditional approval (mid 2020
  3. Vamorolone "VISION-DMD" trial results (Q3 2020)

Santhera Valuation Report "All-in on DMD"